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Purpose: Several methods have been developed for assessing medication-taking behavior; 
understanding the determinants and variability in estimates obtained is crucial in interpreting 
results. We estimated persistence and adherence levels to new glucose-lowering drugs (GLDs) 
in type 2 diabetes mellitus (T2DM) patients using different methods: through the collection of 
pharmacy records and combining pharmacy records with self-reported data.
Methods: We conducted a prospective observational cohort study of T2DM patients initiat-
ing a new GLD. Data were collected at baseline through interviews (demographic and clinical 
data). Follow-up data included pharmacy records (refill dates and medication possession) and 
telephone questionnaires (self-declared monitored GLD refill in another pharmacy, reasons for 
drug withdrawal). The cohort was divided into incident and prevalent new users. Persistence 
and adherence (proportion of days covered) were estimated for patients using pharmacy records 
exclusively (Method 1) and $1 self-declared statement of being persistent (Method 2). Log-rank 
tests were used to compare Kaplan–Meier curves of time to nonpersistence.
Results: A total of 1,328 patients were recruited. When considering Method 1, 38.7% (95% 
confidence interval [95% CI]: 36.0–41.5) of patients were persistent, whereas combining with 
self-reported information, this estimate increased to 65.6% (95% CI: 62.9–68.2). Using Method 1, 
the risk of persistence failure was associated with using an oral GLD, living alone and living 
in a suburban/urban setting. Three hundred and twenty-seven (24.8%) patients stopped to use 
the inception GLD.
Conclusion: Regardless of the method used, results indicated low levels of persistence and 
adherence to a new GLD; however, when combining self-reported information, higher estimates 
were obtained. Considering pharmacy records exclusively, prevalent new users, who were more 
complex patients in terms of T2DM disease but more likely to be pharmacy-loyal patients, were 
significantly more adherent than the incident new users. Barriers and reasons leading to GLD 
withdrawal, namely adverse drug event management, should be addressed, since they represent 
half of the reasons for treatment switching or discontinuation.
Keywords: type 2 diabetes mellitus, medication use behavior, discontinuation, daily practice
Introduction
Type 2 diabetes mellitus (T2DM) is a serious illness, leading to severe complications1,2 
and increased mortality.3 Considering the demographic trends, diabetes prevalence is 
expected to rise to .690 million people by 2,045, posing a major health concern to 
many countries worldwide.4 Portugal is no exception,5 and according to the International 
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Diabetes Federation figures, is one of the countries with the 
highest prevalence of this condition in Europe.6
Achieving and maintaining glycemic control as a 
primary treatment goal is challenging. In general, T2DM 
treatment is carried out in a stepwise manner, initially with 
lifestyle modifications, followed by metformin, and subse-
quently by adding another glucose-lowering drug (GLD).7,8 
Although it is recognized that persistence and adherence to 
medication is crucial to obtain optimal clinical outcomes,9,10 
studies have shown that recommended glycemic goals are 
achieved by ,50% of patients, suggesting poor levels of 
these metrics.11
Several new GLDs, such as dipeptidyl peptidase-4 
inhibitor (DPP-4), glucagon-like peptide-1 (GLP-1) and 
sodium–glucose co-transporter 2 inhibitors, have recently 
been marketed, enabling physicians to tailor therapy through 
a range of combination strategies. In order to target these 
new agents to T2DM patients in actual clinical practice, it is 
essential to monitor and understand the use behavior outside 
of a clinical trial setting.12 This is especially relevant among 
treatment-experienced patients13 where information is scarce, 
as published studies usually come from treatment-naïve or 
selective T2DM patients’ groups with strict eligibility cri-
teria, which represent only a small part of the real-life user 
population.14
Efforts to accurately measure and improve persistence 
and adherence have received increased attention from health 
systems. Several methods and measures have been proposed 
using different data sources and definitions analysis; hence, 
understanding the variability in obtained estimates is crucial 
in interpreting the results.15–17 Unlike much of the existing 
GLD persistence and adherence studies, which used second-
ary data known to be often poor in covariates, namely large 
claims databases,11,18,19 we used primary data originally col-
lected for this research purpose, thus taking increased control 
over available information.20–23
We estimated persistence and adherence levels using 
two methods (the collection of pharmacy records and their 
combination with self-reported information on medication 
use behavior), within 6 months of initiating treatment with a 
new GLD. Additionally, we examined reasons for switching 
or discontinuation and identified potential factors associated 
with nonpersistence and nonadherence among different GLD 
user profiles. This study was conducted in Portugal, which is 
one of the European countries with the highest consumption 
rate of novel GLD,24 and where, unlike many other countries, 
pharmacy records are not centralized.
Methods
study design, setting and population
An intensive monitoring design, defined as an observational, 
prospective cohort study of adult T2DM patients initiating one 
of the recently launched GLDs (inception cohort), recruited by 
community pharmacies, was conducted between November 15, 
2014 and November 30, 2015. Invitation letters were sent to 
all pharmacies from the National Association of Pharmacies 
that satisfied the inclusion criteria (ie, required software, 
participation in at least one research study in the previous 
4 years and had an average daily sale of $1 DPP-4/GLP-1 
package) (n=1,979; 67.8% of all Portuguese pharmacies). The 
pharmacists who agreed to participate were invited to attend a 
training session in which the study was explained.
The eligible study population consisted of first users of the 
new GLD (defined as users who did not take the inception-
monitored drug within the 6 months prior to recruitment, as 
self-reported by the patients) that were that were reimbursed 
in Portugal at the time of enrollment: DPP-4 (sitagliptin, 
vildagliptin, saxagliptin and linagliptin) alone or in fixed-
dose combination with metformin, GLP-1 (liraglutide and 
exenatide) or SLGT-2 (dapagliflozin). In this context, the 
inception drug corresponded to the GLD within the monitored 
therapeutic classes (DPP-4, GLP-1 or SLGT-2) which the 
patient was identified with at cohort entry. As previously 
proposed by Suissa et al,13 our study cohort was divided into 
two subgroups on the basis of participants’ T2DM treatment 
experience: subgroup 1 – incident new users (patients who 
used one of the monitored drugs for the first time [inception 
drug] and had no prior experience with DPP-4, GLP-1 or 
SLGT-2) and subgroup 2 – prevalent new users (patients 
who had previously used at least one GLD of the monitored 
antidiabetic drug classes [DPP-4, GLP-1 or SLGT-2], but 
not the inception-monitored drug). For the eligible subjects 
who did not wish to participate, information regarding age 
group and gender was collected through a refusal log form.
Data collection
Data were collected through three different sources. At 
baseline, patients had a structured face-to-face interview 
with a pharmacist to collect the sociodemographic (birth 
date, gender, highest educational level completed, co-
residence status and number of people living in the subject’s 
household), anthropometrics (weight and height were mea-
sured at enrollment by pharmacy staff in order to calculate 
the body mass index [BMI] which was categorized as 
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Persistence and adherence to new antidiabetic therapy
overweight: 25.0–29.9 kg/m2 and obese: $30 kg/m2) and 
clinical characteristics (age at time of T2DM diagnosis, usual 
diabetes outpatient clinical care [eg, primary care, hospital-
specialized diabetes care appointments, private practice], 
T2DM treatment [dose and prescribed posology of inception 
GLD and other current and past treatments], diabetes-related 
complications [eg, retinopathy, nephropathy, diabetic foot], 
comorbidities and concomitant therapy).
Over the study period, data regarding persistence and 
adherence (eg, refill dates and medication possession) were 
collected by an electronic data capture system developed 
for the electronic extraction of pharmacy records, from the 
pharmacy where the participant was recruited. Follow-up data 
also included structured telephone questionnaires conducted 
2 weeks, 3 months and 6 months after the reported index 
date (starting date of the inception-monitored GLD), where 
information about the real pattern of use was asked. When the 
subjects were identified as potentially nonpersistent through 
the pharmacy records database (which was checked prior to 
each telephone questionnaire administration), the questions 
for confirmation of nonpersistence status (eg, acquisition of 
inception GLD from a different pharmacy, and if yes, the 
number of packages refilled and the corresponding refill 
dates) were asked. If the patients confirmed inception GLD 
withdrawal, reasons for drug discontinuation or switching 
(defined as withdrawal of monitored drug and initiation 
of another GLD) were collected (eg, adverse drug events 
conceivably considered to be associated with the use of 
inception drug, physician’s decision, economic reasons and 
poor glycemic control, among other reasons). In the case of 
switching, information about the new GLD prescribed was 
recorded. To minimize the potential recall bias, a maximum 
4-week period was allowed to obtain responses from the 
telephone questionnaires. However, the patient would still be 
invited to complete the following questionnaire if a response 
was not obtained within this period. Follow-up ceased when-
ever a patient confirmed switching or discontinuation of the 
inception GLD.
Data analysis
Discrete variables were summarized by absolute and relative 
counts. Continuous variables were summarized using cen-
tral tendency measures and dispersion (mean and standard 
deviation [SD]; median and interquartile range [IQR]). Chi-
square test or Fisher’s exact test was used to compare the 
characteristics between subgroups, as well as the distribution 
of refusals with the distribution of participants.
Overall persistence and adherence were calculated through 
two different methods: Method 1 – using pharmacy records 
exclusively and Method 2 – using pharmacy records and their 
combination with patients’ self-reported data on persistence 
collected during the telephone follow-up questionnaires (incep-
tion GLD refilled in a different pharmacy). The proportion of 
pharmacy-loyal patients, defined as those who always refilled 
the inception GLD at the same pharmacy, was calculated.
Persistence was defined as the accumulation of time from 
initiation to withdrawal (switching or discontinuation) of the 
monitored treatment, based on the number of consecutive 
days of inception GLD dispensed to the subject through phar-
macies within a grace period of 30 days (after the supply from 
the previous prescription was exhausted). A nonpersistent 
subject was defined as one who missed prescription cycles 
according to the definition of persistence and was considered 
nonpersistent for the remainder of the study period, regardless 
of whether the subject had refilled the inception GLD for the 
subsequent months. In Method 2, self-reported information 
on the number of packages refilled and the refill dates was 
used. Time to nonpersistence was calculated as the time in 
days between the index date and the last day the patient was 
still classified as persistent. The refill interval considered in 
the analysis was calculated using the baseline information of 
the real prescribed posology, when available. Whenever that 
information was missing, we used the information provided 
by the drug’s summary of product characteristics. Patients 
were censored in the survival analysis if they were lost to 
follow-up (subjects who could not be reached by telephone 
or those who withdrew consent), died or were hospitalized. 
Kaplan–Meier (KM) curves, 95% confidence interval (CI) 
and log-rank test were computed to compare the time to 
nonpersistence between subgroups. A sensitivity analysis 
was conducted for both methods using a grace period of 
14 days. Cox models were used to explore potential factors 
that could contribute to time to nonpersistence. Univariate 
and multivariate hazard ratios (HRs) were computed and 
Wald’s 95% CI presented. In the multivariate model-building 
strategy, KM curves for all covariates were plotted univari-
ately, as the first step. Subsequently, a stepwise selection 
was implemented (significance levels of 0.20 and 0.25 for 
a variable to enter and to stay in the model, respectively). 
Model diagnoses comprised the computation of likelihood 
ratio, Wald and score Chi-square statistics and the variance 
inflation factor (VIF). In-depth residuals analysis, including 
plots with the scaled Schoenfeld residuals, was performed, 
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Adherence was computed for each participant based on the 
proportion of days covered (PDC). PDC was calculated as the 
number of days of medication supplied within the refill inter-
val divided by the number of days of the observation period. 
By calculating the PDC, the proportion of days for which the 
inception GLD was available during the observation period 
was assessed. Overlapping refill days were moved forward to 
the first day that the patient would not have medication from 
the previous dispensing. In Method 2, self-reported information 
on the number of packages refilled and refill dates was used 
to estimate adherence. A patient was classified as adherent 
when PDC was $80%.15,25,26 Patients were excluded from the 
analysis if they were lost to follow-up, died, were hospitalized 
or stopped the inception GLD after a physician’s decision. 
Adherence level estimates were compared between subgroups. 
A sensitivity analysis was performed to take into consideration 
patients who stopped the inception GLD by physician decision, 
and new estimates of adherence levels were obtained including 
these patients. Logistic regression was used to explore the fac-
tors associated with nonadherence. Univariate and multivariate 
odds ratio (OR) and Wald’s 95% CI were estimated. In the 
model-building strategy, all variables were evaluated univari-
ately, as the first step. Subsequently, a stepwise selection was 
implemented (significance levels of 0.20 and 0.25 for a variable 
to enter and to stay in the model, respectively). Model diagnoses 
comprised the calculation of Hosmer and Lemeshow goodness-
of-fit test and VIF. In-depth residuals analysis including plots 
with deviance residuals was performed.
All tests were two-sided and the statistical significance 
level adopted was 5%. Data analysis was performed using 
SAS® software.
ethics and data protection
This study was approved by the Portuguese Data Protec-
tion Authority (5339/2014) and by the Ethics Committee 
of the Institute of Public Health of the University of Porto 
(CE14021), and was conducted in accordance with the ethical 
principles stated in the Declaration of Helsinki. A written, 
signed informed consent form was obtained from all par-
ticipants prior to initiation of any study procedures. This 
study was registered in the European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance E-register of 
studies (ENCEPP/SDPP/8433).
Results
Pharmacies and patients flow
A total of 670 (33.9%) pharmacies agreed to participate in 
the study, out of which 385 (19.5%) pharmacies recruited at 
least one patient. Regional (p=0.0974) and urban/suburban/
rural setting (p=0.3716) distribution of pharmacies with 
recruited patients was similar to the national distribution of 
pharmacies, but participating pharmacies had significantly 
more pharmacists, in their staff (p,0.0001). A total of 1,569 
patients were invited to participate, of whom 231 (14.7%) 
refused to participate and 10 were excluded because they 
did not satisfy the eligibility criteria. Compared to the 
study participants, refusals had similar (p.0.05) age and 
gender distributions. A total of 1,328 eligible patients were 
considered: 61.3% were incident new users and 38.7% were 
prevalent new users. Patient flow and the respective response 
rate per questionnaire are available in the Supplementary 
material.
Baseline population characteristics
Participants’ demographic and clinical characteristics are 
depicted in Table 1. Slightly more than half of the cohort 
were male (n=673; 50.7%) and the mean age was 64.1 
(SD=11.4) years. Approximately two-thirds (66.7%; n=865) 
had only completed 9 years of education, and 84.3% were 
living in household with at least two people (n=1,115). At 
cohort entry, the median BMI and T2DM duration were 
30.1 (IQR=26.8–33.7) kg/m2 and 8.0 years (IQR=3.0–15.0), 
respectively. About one-quarter (n=317; 24.1%) of patients 
self-reported having at least one diabetes-related complica-
tion, with retinopathy (n=225; 17.1%) being the most fre-
quent. Prevalent new users reported a significantly higher 
T2DM duration, prevalence of diabetes-related complications 
and follow-up by a specialist diabetes physician at hospital, 
compared with incident new users.
In addition to T2DM, 88.7% (n=1,176) self-reported 
having chronic illnesses, with hypertension (71.8%; n=952) 
and dyslipidemia (55.9%; n=741) being the most frequent. 
No statistically significant differences were found between 
subgroups regarding the most common chronic illnesses 
and the number of different medicines taken in addition to 
T2DM treatment.
Results showed that 9.7% (n=128) of patients were 
treatment-naïve for T2DM, 66.6% (n=884) were receiving 
other antidiabetic therapy than the inception GLD and 18.7% 
(n=248) were currently taking insulin. Overall, prevalent new 
users were significantly more likely to receive another antidi-
abetic therapy, including insulin, compared with incident 
new users. A total of 905 (68.2%) patients reported having 
changed (including switching, discontinuation or intensifica-
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Persistence and adherence to new antidiabetic therapy
Persistence and potential factors 
associated with time to nonpersistence
KM analysis (Figure 1) showed that overall persistence to the 
inception GLD, which was estimated exclusively with elec-
tronic data from pharmacy records (Method 1), was 38.70% 
(95% CI: 35.98–41.40), whereas including patient self-
reported information on persistence (Method 2) was 65.61% 
(95% CI: 62.91–68.16). In both estimates, persistence rates 
were similar between cohort subgroups (p.0.05). Sensitivity 
analysis using a 14-day grace period revealed lower levels of 
persistence estimates; however, no differences were observed 
between subgroups irrespective of the method used. Differ-
ences were found in the level of pharmacy loyalty, whereas 
significantly (p=0.0035) higher proportion of loyal patients 
was found within the prevalent new users subgroup (67.5% 
of prevalent new users and 32.6% of incident new users were 
considered loyal patients). 
In the multivariate Cox analysis, differences were found 
between the two methods regarding the factors associated 
with the risk of persistence failure (Table 2). When consid-
ering pharmacy records exclusively, patients living alone 
(HR=1.302; 95% CI: 1.058–1.602) and living in urban/
suburban setting (HR=1.580; 95% CI: 1.134–2.203) had a 
significantly higher risk of persistence failure. Conversely, 
subgroup with GLP-1 inception-monitored treatment patients 
had a significantly lower risk of persistence failure than 
patients using an inception oral GLD. Analysis combining 
both pharmacy records and self-reported information showed 
that increasing age was the only factor significantly associ-
ated with the risk of persistence failure (1.6% increase in risk 
of persistence failure for every 1-year increase in age).
Over the study period, a total of 327 (24.8%) patients 
stopped using the inception GLD: 186 (22.9%) incident and 
141 (27.4%) prevalent new users. Withdrawal rates were 
similar (p=0.0591) between subgroups. The most reported 
reasons given for inception GLD withdrawal were physician 
decision (61.5%), followed by adverse drug event (ADE) 
(53.5%), poor glycemic control (23.2%) and patient decision 
(7.3%). One ADE met the criteria of seriousness (hospitaliza-
tion) and was reported to the national spontaneous reporting 
system, where it was handled according to the regulations 
regarding serious reports. Treatment switching recom-
mended by physician was recorded for 137 (41.8%) cases 
who stopped inception GLD (93 DPP-4 alone or in fixed-
dose combination with metformin, 31 dapagliflozin, eight 
exenatide and five liraglutide). Among patients administered 
DPP-4 alone or in fixed-dose combination with metformin, it 
was noted that 50.5% (n=47) switched within the same drug 
class, whereas among dapagliflozin inception users, 29.0% 
(n=9) and 25.8% (n=8) switched to fixed-dose combinations 
of DPP-4 with metformin and insulin, respectively.
Adherence and potential factors associated 
with nonadherence
At the end of the study, when adherence estimates considered 
patient self-reported information (Method 2), 73.6% (95% CI: 
70.9–76.3) of participants were adherent (PDC $80%). 
No significant differences were observed between sub-
groups (p=0.1614). However, when adherence rates were 
estimated exclusively considering electronic data from 
pharmacy records (Method 1), a significant higher proportion 







n (%) n (%)
gender (male) 420 (51.60) 253 (49.22) 0.3991
Age (years) 0.2548
,55 159 (19.83) 105 (20.55)
55–64 225 (28.05) 154 (30.14)
65–74 259 (32.29) 173 (33.86)
$75 159 (19.83) 79 (15.46)
nr=15
Diabetes duration (years) ,0.0001
,1 116 (15.87) 12 (2.43)
1–5 224 (30.64) 116 (23.48)
6–9 102 (13.95) 66 (13.36)
$10 289 (39.53) 300 (60.73)
nr=103
BMi (kg/m2) 0.0215
,25.00 104 (13.07) 63 (12.48)
25.00–29.99 314 (39.45) 164 (32.48)
$30.00 378 (47.49) 278 (55.05)
nr=27
chronic diseases 0.1627
0 86 (10.58) 64 (12.48)
1–2 547 (67.28) 319 (62.18)
$3 180 (22.14) 130 (25.34)
number of different medicines 0.2645
0 46 (5.82) 23 (4.53)
1–2 218 (27.59) 124 (24.41)
3–4 250 (31.65) 160 (31.50)
$5 276 (34.94) 201 (39.57)
Diabetes-related complications
Yes 166 (20.54) 151 (29.72) 0.0001
retinopathy 112 (13.86) 113 (22.24) ,0.0001
nephropathy 70 (8.66) 50 (9.84) 0.4694
nr=12
Diabetic foot 42 (5.20) 41 (8.07) 0.0369
current use of insulin 111 (13.64) 137 (26.65) ,0.0001
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of nonadherents was found among incident new users 
(p=0.0112; Table 3). Adherence sensitivity analysis (patients 
who stopped the inception drug due to physician decision 
were included) revealed lower levels of adherence estimates 
(Method 1: 35.9% [95% CI: 33.8–39.2]; Method 2: 63.9% 
[95% CI: 63.5–64.6]), yet no differences were observed 
between subgroups irrespective of the method used. In the 
multivariate regression analysis, although differences were 
found between the two methods, factors associated with 
nonadherence (Table 4) were overall similar with those found 
in the risk of persistence failure analysis. In both methods, 
living alone and using an oral inception GLD were factors 
associated with nonadherence.
Discussion
Contrasting with most published studies that use claims 
databases to measure persistence and adherence, we used an 
intensive monitoring design that collected information from 
the first day of drug use and explored the differences between 
two methods, namely pharmacy records and their combina-
tion with patient self-reported data, each yielding different 
estimates. The use of patient self-reports also allowed us to 
explore the important features of medication-taking behavior, 
namely reasons for treatment switching or discontinuation, 
which are not often captured in administrative databases. As 
with other chronic diseases, low persistence rates for new 
GLD were found: 38.7% considering information exclusively 
from pharmacy records and 65.6% in combination with 
self-reported information. Almost two-thirds of patients 
were identified as nonadherent when considering pharmacy 
records exclusively, which decreased to almost one-quarter 
of patients, when including patient self-reported data.
Overall, considering the persistence and adherence esti-
mates obtained in this study, together with sensitivity analysis 
Figure 1 Persistence and KM curves to inception-monitored glucose-lowering drug at 6 months of follow-up.
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Persistence and adherence to new antidiabetic therapy
Table 2 Factors associated with time to nonpersistence to the inception monitored glucose loweing drug (Method 1: pharmacy 
records exclusively and Method 2: combination of pharmacy records and self-reported information)
Variable Method 1: pharmacy records 
exclusively











incident new users reference reference
Prevalent new users 0.899 (0.777–1.041) 1.082 (0.894–1.310)
gender
Female reference reference
Male 0.992 (0.861–1.143) 1.052 (0.872–1.270)
Age (years) 0.997 (0.991–1.004) 0.995 (0.988–1.002) 1.013 (1.005–1.022) 1.016 (1.007–1.025)
BMi (kg/m2) 0.996 (0.982–1.010) 0.990 (0.972–1.009)
educational level
no degree and basic education (#9 years) reference reference
secondary and university degree (.9 years) 1.032 (0.868–1.228) 0.955 (0.755–1.208)
living alone
no reference reference reference
Yes 1.256 (1.042–1.514) 1.302 (1.058–1.602) 1.269 (0.994–1.619)
setting of residence
rural reference reference reference
Urban/suburban 1.490 (1.112–1.995) 1.580 (1.134–2.203) 1.162 (0.807–1.674)
inception-monitored drug treatment group
glP-1 reference reference reference
Others 1.393 (1.096–1.771) 1.389 (1.074–1.797) 1.274 (0.927–1.752)
chronic diseases
no reference reference reference
Yes 0.773 (0.628–0.953) 0.788 (0.620–1.001) 0.955 (0.715–1.276)
Diabetes duration (years) 0.996 (0.987–1.005) 1.004 (0.992–1.015)
Diabetes-related complications
no reference reference
Yes 0.982 (0.832–1.160) 0.963 (0.771–1.202)
current use of insulin
no reference reference reference 
Yes 0.781 (0.645–0.945) 0.851 (0.663–1.093) 0.841 (0.646–1.095)
Notes: *Wald test: p=0.0002; ViF#1.12. **Wald test: p=0.0014; ViF#1.01.
Abbreviations: BMI, body mass index; CI, confidence interval; GLP-1, glucagon-like peptide-1; HR, hazard ratio; VIF, variance inflation factor.
Table 3 Adherence to inception-monitored glucose-lowering drug
Total Incident new users Prevalent new users p-value
Method 1 – pharmacy 
records exclusively
Adherent (PDc$80%) % [95% ci] 41.29% [38.27–44.31] 38.23% [34.45–42.02] 46.27% [41.32–51.23] 0.0112
PDc classes [0–20] 11.64% 11.22% 12.34% 0.0570
[20–40] 12.04% 13.43% 9.77%
[40–60] 12.62% 12.95% 12.08%
[60–80] 22.41% 24.17% 19.54%
[80–100] 41.29% 38.23% 46.27%
Method 2 – pharmacy 
records+patient self-
reported information
Adherent (PDc$80%) % [95% ci] 73.57% [70.87–76.26] 72.06% [68.57–75.54] 76.02% [71.79–80.25] 0.1614
PDc classes [0–20] 5.25% 4.71% 6.12% 0.2317
[20–40] 4.08% 4.08% 4.08%
[40–60] 3.30% 3.61% 2.81%
[60–80] 13.80% 15.54% 10.97%
[80–100] 73.57% 72.06% 76.02%
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results, we believe that the “true” persistence/adherence rates 
reported for the new GLD might possibly be between the 
lower limit of estimates retrieved from pharmacy records 
exclusively and the upper limit of estimates retrieved from the 
combination of pharmacy records and patient self-reported 
information. From this perspective, it is assumed that, on the 
one hand, patient self-reported information on medication-
taking behavior could overestimate the results. On the other 
hand, over a 6-month period, given that, in Portugal, patients 
can go to more than one pharmacy and there is no single 
database that records all prescription refills from different 
pharmacies at an individual patient level, estimates retrieved 
exclusively from pharmacy records could be underestimated. 
More than one-third of patients who started the monitored 
GLD self-declared at least one refill in a different pharmacy 
where they were recruited.
Regardless of these assumptions, at 6 months from therapy 
initiation, persistence and adherence rates observed, although 
very low, were in line with, or to some extent lower than, the 
existent literature. A recent systematic review of observational 
studies revealed a persistence mean rate to T2DM medication 
of 56.2% (95% CI: 46.1–66.3).27 However, it should be noted 
that the included studies in the review had a longer follow-up 
period than our study, and pharmacy or prescription records 
data used in the studies were centralized. Concerning adher-
ence, in another recent systematic review of 27 studies pub-
lished between 2003 and 2014,28 it was found that the levels 
ranged from 38.5% to 93.1%, based on surveys on specific 
instruments or on claims databases. When considering only 
studies that used the medication possession ratio methodol-
ogy (in general, for a follow-up duration of 12 months), the 
prevalence of adherence ranged between 46.0% and 89.8%.
Table 4 Factors associated with nonadherence to inception-monitored glucose-lowering drug (Method 1: pharmacy records 
exclusively and Method 2: combination of pharmacy records and self-reported information)
Variable Method 1: pharmacy records 
exclusively











incident new users reference reference reference
Prevalent new users 0.719 (0.556–0.928) 0.802 (0.604–1.066) 0.813 (0.609–1.086)
gender
Female reference reference
Male 1.031 (0.804–1.323) 1.168 (0.885–1.542)
Age (years) 0.981 (0.970–0.993) 0.968 (0.955–0.981) 1.013 (1.000–1.026)
BMi (kg/m2) 1.004 (0.980–1.028) 0.997 (0.970–1.025)
educational level
no degree and basic education (#9 years) reference reference
secondary and university degree (.9 years) 1.013 (0.747–1.374) 0.897 (0.635–1.268)
living alone
no reference reference reference reference
Yes 1.677 (1.166–2.412) 2.020 (1.345–3.033) 1.600 (1.114–2.297) 1.645 (1.117–2.424)
setting of residence
rural reference reference
Urban/suburban 1.360 (0.871–2.122) 0.753 (0.466–1.216)
inception-monitored drug treatment group
glP-1 reference reference reference reference
Others 1.845 (1.252–2.719) 1.697 (1.082–2.661) 1.980 (1.186–3.305) 1.859 (1.093–3.161)
chronic diseases
no reference reference
Yes 0.664 (0.439–1.005) 1.061 (0.679–1.659)
Diabetes duration (years) 0.986 (0.971–1.001) 0.995 (0.978–1.012)
Diabetes-related complications
no reference reference reference
Yes 1.030 (0.771–1.376) 1.356 (0.983–1.870) 0.969 (0.701–1.341)
current use of insulin
no reference reference reference
Yes 0.576 (0.419–0.792) 0.713 (0.494–1.029) 0.716 (0.489–1.047)
Notes: *Hosmer and Lemeshow goodness-of-fit test, p=0.9914; ViF#1.196. **Hosmer and Lemeshow goodness-of-fit test, p=0.8785; ViF#1.004.
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Persistence and adherence to new antidiabetic therapy
With regard to factors that could contribute to nonpersis-
tence and nonadherence, irrespective of the differences found 
between each method, they were broadly in line with what 
has been described in previous studies elsewhere. When com-
bining pharmacy records with patient self-reported informa-
tion, it was observed that increasing age was the only factor 
associated with persistence failure risk.11 Yet, when analyzing 
pharmacy records only, patients living alone,29 living in a 
suburban/urban setting30,31 and using an oral inception GLD 
had a higher risk of persistence failure. The later disputes 
findings from previous studies,32,33 although comparison 
studies using the new GLD for persistence and adherence, 
are scarce due to its recent availability in the market.
The overall clinical demographics of our study partici-
pants were generally similar to a large Portuguese T2DM 
patient cohort analyzed in 2013, in a primary care setting. 
From the data available, we found that our study population 
had comparable gender distribution, mean age and similar 
distribution regarding the most frequent comorbidities.34 The 
prevalent new users subgroup, representing almost two-fifths 
of all participants, had a significant higher T2DM duration, 
a higher prevalence of diabetes complications, use of insulin 
and use of specialist care visits, compared with incident new 
users. This was not surprising, as T2DM is a progressive 
condition, and therefore, prevalent new users are more likely 
to be complex patients.35,36
Given the differences observed in T2DM characteristics 
between incident and prevalent new user subgroups, we 
would expect dissimilar persistence and adherence results. 
However, rates estimated through the two methods were 
comparable overall. Only adherence estimates consider-
ing pharmacy records exclusively showed that prevalent 
new users (46.3%; 95% CI: 41.3–51.2) were significantly 
(p=0.0112) more adherent than incident new users (38.23%; 
95% CI: 34.5–42.0). This could be explained partially by the 
fact that a significantly higher proportion (almost double: 
67.5% versus 32.6%) of pharmacy-loyal patients was found 
among the prevalent new user subgroup. Our findings are 
consistent with the literature. In a recent study conducted 
in the Canadian province of Quebec, it was observed that 
pharmacy-loyal patients were more likely to be adherent 
(PDC$80%) with T2DM medication (OR=1.22; 95% CI: 
1.19–1.26).37 The positive association between pharmacy 
loyalty and persistence or adherence has also been demon-
strated with other therapeutic groups, such as that including 
antipsychotic treatment38 and cardiovascular medication.39 
Similarly, a study from the USA that included older adults 
with Medicare Part D demonstrated that filling prescriptions 
at multiple pharmacies, which was a prevalent phenomenon 
(38.1% of beneficiaries), was associated with lower medica-
tion adherence across a range of chronic medications.40
Over the study period, almost one-quarter of participants 
stopped using the inception GLD. These results are slightly 
lower than some reports from other studies, where a higher 
stopping rate of 31.4% was found.27 Our study adds informa-
tion on commonly reported reasons for discontinuation from 
the patients’ perspective, which are not frequently captured 
in database studies. Physician decision, followed by ADE 
and reported poor glycemic control, was the most frequent 
reason stated for interrupting the inception GLD. It should be 
emphasized that among patients who stopped the inception 
GLD due to physician decision, only 67% switched to another 
antidiabetic drug, commonly the drug they were taking prior 
to recruitment. In these cases, conflicting decisions between 
doctors (primary care versus specialists) were frequently the 
reason, as some patients in our study declared. Addressing 
early risk of treatment failure for the new GLD should be put 
in place, and improvements in patient–health care provider 
communication as well as between health care providers 
are required. Furthermore, proactive management of ADE, 
including those which are expected and transient, but which 
may lead to unnecessarily early therapy discontinuation, 
should be a priority. In particular, clinicians should closely 
monitor patients with previous discontinuations related to 
ADE, because it is assumed that these patients might have an 
increased susceptibility to ADE compared to others.41
The results of the present study should be viewed in light 
of the following limitations. First, although it has been dem-
onstrated that patients’ self-reported GLD utilization patterns 
are reliable,42 the use of self-reported information to ascertain 
medication-taking behavior could be biased by a reluctance 
to admit inappropriate behavior (social desirability bias); 
hence, a potential misclassification bias of patients being clas-
sified as persistent should be considered. Notwithstanding, 
inaccuracies in self-reported information are believed to be 
minimized, since independent research interviewers and not 
patients’ health care providers were responsible for conduct-
ing the follow-up interviews.43,44 Even when including patient 
self-reported information, the rates found were still very low; 
that is to say, the majority of patients did not show reluctance 
to declare they had stopped taking the medication. Second, 
persistence estimates were calculated on an individual drug 
level, and the impact of switching to other antidiabetic medi-
cation during the study period was not assessed.
Despite the mentioned limitations, this study has sev-
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pharmacy-based intensive monitoring model, which is a 
noninterventional inception cohort study mirroring the real 
use of new GLD, prescribed by both general practitioners 
and specialists, with no limiting inclusion (with the excep-
tion of a T2DM treatment indication) or exclusion criteria 
compared with clinical trials. Further, although self-selection 
of pharmacies could have occurred since participation was 
not mandatory, it seems reasonable to assume that the study 
sample is representative of the overall country population 
of TDM2 patients taking new GLD, given the similarities 
found with the reference population and since pharmacies 
included were representative of the Portuguese pharmacies. 
Also, refusals had a similar age and gender distribution as 
compared to the study participants, and several strategies to 
minimize patients’ nonsystematic selection were put in place 
during the enrollment period (namely pop-up reminders at the 
pharmacy software whenever a new GLD was dispensed). 
Finally, this study provided a good source for persistence/
adherence investigation because, on the one hand, data were 
collected directly from pharmacy dispensing, rather than 
physicians’ prescriptions that may never be dispensed. This 
is of relevance, as primary nonadherence is a frequent phe-
nomenon: it was identified in almost a quarter of patients in 
both the USA45 and Portugal.46 On the other hand, as previ-
ously highlighted, patient self-reported usage data may well 
collect and explore the important features of medication use 
and behavior, namely reasons for treatment discontinuation, 
which are not captured in claims databases.47
Conclusion
Regardless of the method used, in case of pharmacy records 
or their combination with patient self-reported informa-
tion, low levels of new GLD persistence and adherence 
were found. The combination of pharmacy records with 
self-reported information yielded higher estimates, even 
though they were in line with existent literature. Adherence 
estimates considering pharmacy records exclusively showed 
that prevalent new users, who were more complex in terms of 
T2DM disease but more likely to be pharmacy-loyal patients, 
were significantly more adherent than incident new users. 
Strategies to improve adherence and persistence should be 
implemented right from the commencement of therapy, and 
continuous attention should be given to nonserious ADE, 
since they represent half of the reported reasons for treatment 
switching or discontinuation.
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Figure S1 Study flow diagram.
Notes: Patients were allowed to fill in a questionnaire even if they had not completed the previous one. Among the eligible patients (1,328), 63.86% (n=848) started one 
DPP-4 alone or in fixed-dose combination with metformin, 11.07% (n=147) one glP-1 and 23.19% (n=308) dapagliflozin. For 25 participants, two different inception GLDs 
were prescribed simultaneously (17 out of 25 started dapagliflozin with DPP-4 [alone or in fixed-dose combination with metformin]); these patients could stop the inception 
glD in different moments. A total of 328 inception-monitored glDs were stopped (24.4% [n=207] DPP-4 alone or in fixed-dose combination with metformin, 28.9% [n=89] 
dapagliflozin and 21.8% [n=32] glP-1).
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